二甲双胍潜在用途研究进展

摘要/Abstract

摘要： 二甲双胍（metformin，MF）是双胍类降糖药物，主要用于治疗II型糖尿病（Type 2 diabetes mellitus, T2DM）和代谢综合征。然而，二甲双胍的实际和潜在的用途已经远远超出了其规定的使用范围。近年来随着对二甲双胍研究的越来越多，该药物在不同情况下的更多作用相继被发现。二甲双胍除了有降低血糖的作用以外还有抗肿瘤作用、抗衰老作用、抗炎作用、菌群改善作用和潜在的成骨作用。本文就二甲双胍在各领域的作用作一综述，为临床和研究人员提供参考。

关键词: 二甲双胍, 抗肿瘤, 抗衰老, 抗炎, 菌群改善作用, 成骨作用

Abstract: Metformin is a biguanide hypoglycemic drug mainly used to treat type 2 diabetes mellitus (T2DM) and metabolic syndrome. However, the potential use of metformin goes far beyond its intended use. In recent years, with more and more studies on metformin, more effects of the drug in different situations have been discovered. In addition to the role of lowering blood sugar, metformin has the effects of anti-tumor, anti-aging, anti-inflammation, modulation of gut microbiota and potential osteogenesis. This article reviews the role of metformin in various fields and provides a reference for clinicians and researchers.

Key words: metformin, anti-tumor, anti-aging, anti-inflammatory, gut microbiota, osteogenesis

中图分类号:

R977.6

张睿葛少华. 二甲双胍潜在用途研究进展 [J]. , 2018, 38(10): 938-941.

Rui ZHANG. Research progress of the potential use of metformin[J]. , 2018, 38(10): 938-941.

参考文献

[1]International Diabetes Federation.IDF diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015
[2]Grzybowska M, Bober J, Olszewska M.Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus[J].Post?py Higieny I Medycyny Do?wiadczalnej, 2011, 65(27):277-
[3]Yerrabothala S, Shaaban H, Capo G, et al.The impact of diabetes mellitus on breast cancer outcomes: a single center retrospective study[J].Pathology & Oncology Research, 2014, 20(1):209-214
[4]Wang J Y, Chao T T, Lai C C, et al.Risk of colorectal cancer in type 2 diabetic patients: a population-based cohort study[J].Japanese Journal of Clinical Oncology, 2013, 43(3):258-63
[5]Lee J Y, Jeon I, Lee J M, et al.Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies[J].European Journal of Cancer, 2013, 49(10):2411-
[6]Gupta S P, Mittal A, Jha D K, et al.Diabetes mellitus and renal cell carcinoma--a hospital based study from Kathmandu Valley[J].Asian Pacific Journal of Cancer Prevention Apjcp, 2012, 13(10):4963-
[7]Xu Y, Wang L, He J, et al.Prevalence and Control of Diabetes in Chinese Adults[J].Jama, 2013, 310(9):948-
[8]Liu X, Hemminki K, F?rsti A, et al.Cancer risk in patients with type 2 diabetes mellitus and their relatives[J].International Journal of Cancer Journal International Du Cancer, 2015, 137(4):903-10
[9]Schneider M B, Matsuzaki H, Haorah J, et al.Prevention of pancreatic cancer induction in hamsters by metformin[J].Gastroenterology, 2001, 120(5):1263-1270
[10]Evans J M M, Donnelly L A, Emsliesmith A M, et al.Metformin and reduced risk of cancer in diabetic patients[J].Bmj, 2005, 330(7503):1304-
[11]Morales D R, Morris A D.Metformin in cancer treatment and prevention[J].Annual Review of Medicine, 2015, 66(1):17-
[12]Tseng C H.Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus[J].European Journal of Cancer, 2014, 50(16):2831-2837
[13]Thakkar B, Aronis K N, Vamvini M T, et al.Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies[J].Metabolism-clinical & Experimental, 2013, 62(7):922-34
[14]Lin H C, Kachingwe B H, Lin H L, et al.Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study[J].Pharmacotherapy, 2014, 34(1):36-45
[15] Coyle C, Cafferty F H, Vale C, et al.Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis[J]. Annals of Oncology. 2016, 27(12):2184-2195.
[16] Libby G, Donnelly L A, Donnan P T, et al.New Users of Metformin Are at Low Risk of Incident Cancer[J]. Diabetes Care. 2009, 32(9):1620.
[17] Higurashi T, Hosono K, Takahashi H, et al.Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. [J]. Lancet Oncology. 2016, 17(4):475-483.
[18] Siddappa G, Kulsum S, Ravindra D R, et al.Curcumin and metformin mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells. [J]. Mol Carcinog. 2017 Nov; 56(11):2446-2460.
[19] Lam T G, Jeong Y S, Kim S, et al.New metformin derivativeHL156A prevents oral cancer progression by inhibiting the insulin‐like growth factor/AKT/mammalian target of rapamycin pathways[J]. Cancer Sci. 2018 Mar; 109(3):699-709.
[20] Cabreiro F, Au C, Leung KY, et al.Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. [J]. Cell. 2013; 153(1):228–239.
[21] Martinmontalvo A, Mercken E M, Mitchell S J, et al.Metformin improves healthspan and lifespan in mice. [J]. Nat Commun. 2013, 4(7): 2192.
[22] Wang C P, Lorenzo C, Espinoza S E.Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes. [J]. J Endocrinol Diabetes Obes. 2014; 2(2)
[23] Bannister C A, Holden S E, Jenkinsjones S, et al.Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. [J]. Diabetes Obes Metab. 2014, 16(11):1165.
[24] Anisimov V N, Berstein L M, Popovich I G, et al.If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice[J]. Aging. 2011, 3(2):148-57.
[25] Hattori, Yoshiyuki, Suzuki, Kunihiro, Tomizawa, Atsuko, et al.Retraction of: Cilostazol inhibits cytokine-induced nuclear factor-κB activation via AMP-activated protein kinase activation in vascular endothelial cells[J]. Cardiovascular Research. 2009, 47(6): 1183.
[26] Kikuo Isoda, James L.Young, Andreas Zirlik, et al. Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells. [J]. Arterioscler Thromb Vasc Biol. 2006, 26(3): 611.
[27] Kang W, Wang T, Hu Z, et al.Metformin Inhibits P. gingivalis Lipopolysaccharide (LPS)-influenced Inflammatory Response in Human Gingival Fibroblasts via Regulating Activating Transcription Factor-3 (ATF3) Expression. [J]. J Periodontol. 2017, 88(10): e169-e178.
[28] Kim J, Kwak H J, Cha J Y, et al.Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. [J]. J Biol Chem. 2014, 289(33): 23246.
[29] Deng J, Zeng L, Lai X, et al.Metformin protects against intestinal barrier dysfunction via AMPKα1-dependent inhibition of JNK signalling activation. [J]. J Cell Mol Med. 2018, 22(1): 546-557.
[30] Nguyen G, Park S Y, Le C T, et al.Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition[J]. Biochem Biophys Res Commun. 2018, 495(4): 2649-2656.
[31] Hur K Y, Lee M.New mechanisms of metformin action: Focusing on mitochondria and the gut. [J]. Journal of Diabetes Investigation. 2015, 6(6): 600-609.
[32] Ussar S, Fujisaka S, Kahn C R.Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. [J]. Molecular Metabolism. 2016, 5(9): 795-803.
[33] Khosravi A, Yá?ez A, Price J G, et al.Gut microbiota promote hematopoiesis to control bacterial infection. [J]. Cell Host Microbe. 2014, 15(3): 374-381
[34] Hernandez C J, Guss J D, Luna M, et al.Links Between the Microbiome and Bone. [J]. J Bone Miner Res. 2016, 31(9): 1638-1646.
[35] Shan L, Konstantinov S R, Smits R, et al.Bacterial Biofilms in Colorectal Cancer Initiation and Progression[J]. Trends Mol Med. 2017, 23(1): 18-30.
[36]NaRi Shin, JuneChul Lee, HaeYoun Lee, et al.An increase in the Akkermansia spppopulation induced by metformin treatment improves glucose homeostasis in diet-induced obese mice[J].Gut, 2014, 63(5):727-35
[37] Amandine Everard, Clara Belzer, Lucie Geurts, et al.Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. [J]. Proc Natl Acad Sci U S A. 2013, 110(22): 9066-71.
[38] Cortizo A M, Sedlinsky C, Mccarthy A D, et al.Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. [J]. Eur J Pharmacol. 2006, 536(1-2): 38.
[39] Kanazawa I, Yamaguchi T, Yano S, et al.Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. [J]. Biochem Biophys Res Commun. 2008, 375(3): 414-9.
[40] Wang P, Ma T, Guo D, et al.Metformin Induces Osteoblastic Differentiation of Human Induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells. [J]. J Tissue Eng Regen Med. 2017.
[41] Molinuevo M S, Schurman L, Mccarthy A D, et al.Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies. [J]. J Bone Miner Res. 2010. 25(2): 211-21
[42]L?e H.Periodontal Disease: The sixth complication of diabetes mellitus[J].Diabetes Care, 1993, 16(1):329-334
[43] Pradeep A R, Rao N S, Naik S B, et al.Efficacy of varying concentrations of subgingivally delivered metformin in the treatment of chronic periodontitis: a randomized controlled clinical trial. [J]. J Periodontol. 2013, 84(2): 212-220.
[44] Pradeep A R, Patnaik K, Nagpal K, et al.Efficacy of locally-delivered 1% metformin gel in the treatment of intrabony defects in patients with chronic periodontitis: a randomized, controlled clinical trial. [J]. J Investig Clin Dent. 2016, 7(3):239-245.
[45] Pradeep A R, Nagpal K, Karvekar S, et al.Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. [J]. J Periodontol. 2015, 86(6):729-37.
[46] Bak E J, Park H G, Kim M, et al.The effect of metformin on alveolar bone in ligature-induced periodontitis in rats: a pilot study. [J]. J Periodontol. 2010, 81(3):412-9.